NOVN.SW
Novartis AG
Price history
Key metrics
Novartis AG has paid a dividend for 30 consecutive years and currently yields 3.21%, below its five year average. Its payout ratio is 63%. Dividend Health rates it Very safe at 81 out of 99, with high confidence.
Data as of 22 Sept 2026
Next dividend
Per share
CHF 3.70
Frequency
Final
Declared
—
Ex-date
9 Mar 2027
in 168 days
Pay date
11 Mar 2027
estimated
Dividend health
Confidence High · Defensive profile · as of 22 Sept 2026
Total return
CHF 10,000 invested is CHF 26,302 today: CHF 4,810 from the share price and CHF 11,492 from dividends reinvested.
Total return +163.02%. Price alone returned +48.10% over the same window.
Assumes every dividend is reinvested on its ex-dividend date, before tax and dealing costs.
How it compares
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Annual dividends per share
Dividends paid in CHF · based on NOVN.SW's fiscal years ending in December
Dividend Policy
Subject to the dividend policy described below, our Board of Directors expects to recommend the payment of a dividend in respect of each financial year. If approved by our shareholders at the relevant annual shareholders' meeting, the dividends will be payable shortly following such approval. Any shareholder who purchases our shares before the ex-dividend date and holds the shares until that date shall be deemed to be entitled to receive the dividends approved at that meeting. Dividends are reflected in our financial statements in the year in which they are approved by our shareholders. Our dividend policy is to pay a growing annual dividend in Swiss francs per share. This policy is subject to our financial conditions and outlook at the time, the results of our operations, and other factors.
Dividend History
| Ex-Date | Amount | Status |
|---|---|---|
| 09 Mar 272027-03-09 | CHF 3.7000 | Estimated |
| 10 Mar 262026-03-10 | CHF 3.7000 | Paid |
| 11 Mar 252025-03-11 | CHF 3.5000 | Paid |
| 07 Mar 242024-03-07 | CHF 3.3000 | Paid |
| 09 Mar 232023-03-09 | CHF 3.2000 | Paid |
| 08 Mar 222022-03-08 | CHF 3.1000 | Paid |
| 04 Mar 212021-03-04 | CHF 3.0000 | Paid |
| 03 Mar 202020-03-03 | CHF 2.9500 | Paid |
| 04 Mar 192019-03-04 | CHF 2.8500 | Paid |
| 06 Mar 182018-03-06 | CHF 2.8000 | Paid |
| 02 Mar 172017-03-02 | CHF 2.7500 | Paid |
| 25 Feb 162016-02-25 | CHF 2.7000 | Paid |
| 03 Mar 152015-03-03 | CHF 2.6000 | Paid |
| 27 Feb 142014-02-27 | CHF 2.4500 | Paid |
| 26 Feb 132013-02-26 | CHF 2.3000 | Paid |
| 27 Feb 122012-02-27 | CHF 2.2500 | Paid |
| 24 Feb 112011-02-24 | CHF 2.2000 | Paid |
| 02 Mar 102010-03-02 | CHF 2.1000 | Paid |
| 27 Feb 092009-02-27 | CHF 2.0000 | Paid |
| 29 Feb 082008-02-29 | CHF 1.6000 | Paid |
| 09 Mar 072007-03-09 | CHF 1.3500 | Paid |
| 03 Mar 062006-03-03 | CHF 1.1500 | Paid |
| 04 Mar 052005-03-04 | CHF 1.0500 | Paid |
| 27 Feb 042004-02-27 | CHF 1.0000 | Paid |
| 07 Mar 032003-03-07 | CHF 0.9500 | Paid |
| 26 Mar 022002-03-26 | CHF 0.9000 | Paid |
| 27 Mar 012001-03-27 | CHF 0.8500 | Paid |
| 17 Apr 002000-04-17 | CHF 0.8000 | Paid |
| 26 Apr 991999-04-26 | CHF 0.7250 | Paid |
| 24 Apr 981998-04-24 | CHF 0.6250 | Paid |
| 25 Apr 971997-04-25 | CHF 0.5000 | Paid |
This page is for informational purposes only and does not constitute investment advice. Past dividend payments are not a guarantee of future payments. All data is sourced from public market data and may be delayed. Always do your own research before making any investment decisions.
Your dividend income, mapped.
Free for up to 25 holdings. No credit card. Import your first portfolio in under a minute.
Get started free